{
    "clinical_study": {
        "@rank": "120881", 
        "arm_group": [
            {
                "arm_group_label": "Tenofovir Monotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Tenofovir 300 mg tablet, orally (PO) once daily for 8 weeks, then Tenofovir 300 mg tablet, PO, once daily for an additional 96 weeks (total treatment duration 104 weeks)"
            }, 
            {
                "arm_group_label": "PegIFN-2b/Tenofovir Sequential Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Tenofovir 300 mg tablet, PO, once daily for 8 weeks, then PegIFN-2b, 1.5 mcg/kg subcutaneously (SC), once weekly, for 24 weeks, then Tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)"
            }, 
            {
                "arm_group_label": "Peg-IFN-2b + Tenofovir Combination Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Tenofovir 300 mg tablet, PO once daily for 8 weeks, then pegIFN-2b, 1.5 mcg/kg SC once weekly and tenofovir 300 mg tablet, PO, once daily for 24 weeks, and then tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will compare monotherapy with tenofovir to sequential therapy with pegylated\n      interferon alpha-2b (pegIFN-2b) followed by tenofovir, and to combination therapy with\n      pegIFN-2b + tenofovir, in participants with hepatitis B e antigen (HBeAg)-positive chronic\n      hepatitis B and elevated alanine aminotransferase (ALT). All enrolled participants will be\n      be administered tenofovir alone for 8 weeks and then will be randomly assigned to 1 of the 3\n      treatment arms."
        }, 
        "brief_title": "A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic hepatitis B (hepatitis B surface antigen [HBsAg]-positive for >6 months or\n             evidence of chronic hepatitis B in liver biopsy)\n\n          -  Elevated serum ALT level\n\n          -  Liver biopsy or a non-invasive investigation within 12 months prior to randomization\n             with Chronic Hepatitis B\n\n          -  Treatment na\u00efve or history of interferon for not more than 1 month, taken at least 6\n             months before enrollment\n\n          -  Compensated liver disease\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to tenofovir, interferon alpha-2b,  and/or any other component\n             of the study products\n\n          -  Co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV) or human\n             immunodeficiency virus (HIV)\n\n          -  Need for prolonged or frequent use of systemic acyclovir or famciclovir\n\n          -  Previously received lamivudine or an investigational anti-hepatitis B virus (HBV)\n             nucleoside or nucleotide analog and were resistant to these drugs\n\n          -  History of variceal bleeding or other GI bleeding due to portal hypertension, hepatic\n             encephalopathy, spontaneous bacterial peritonitis, Grade III and IV esophageal\n             varices unless banded or other clinical signs of hepatic decompensation\n\n          -  History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC\n\n          -  Need for potentially hepatotoxic drugs (e.g. dapsone, erythromycin, fluconazole,\n             ketoconazole, rifampin, and anti-tuberculosis regimens) or nephrotoxic drugs (e.g.\n             frequent nonsteroidal anti-inflammatories, aminoglycosides, amphotericin B, and\n             foscarnet)\n\n          -  One or more additional known primary or secondary causes of liver disease, other than\n             hepatitis B\n\n          -  History of clinical pancreatitis\n\n          -  Pregnant or breastfeeding\n\n          -  Female participants of childbearing potential and male participants must be willing\n             to use acceptable method of birth control.\n\n          -  Medical condition that requires frequent or prolonged use of systemic corticosteroids\n\n          -  Use of warfarin or other anticoagulants during 30 days prior to screening or if\n             expected to be needed during the study period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01727271", 
            "org_study_id": "4031-384"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Tenofovir Monotherapy", 
                    "PegIFN-2b/Tenofovir Sequential Therapy", 
                    "Peg-IFN-2b + Tenofovir Combination Therapy"
                ], 
                "intervention_name": "Tenofovir", 
                "intervention_type": "Drug", 
                "other_name": "Truvada"
            }, 
            {
                "arm_group_label": [
                    "PegIFN-2b/Tenofovir Sequential Therapy", 
                    "Peg-IFN-2b + Tenofovir Combination Therapy"
                ], 
                "intervention_name": "Pegylated interferon alpha-2b", 
                "intervention_type": "Biological", 
                "other_name": [
                    "SCH 054031", 
                    "MK-4031"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferon Alfa-2b", 
                "Interferons", 
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Peginterferon alfa-2b", 
                "Reaferon"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 18, 2013", 
        "number_of_arms": "3", 
        "official_title": "An Open-Label, Pilot, Randomized, Multi-Center Study to Compare Efficacy and Safety of Tenofovir Monotherapy Alone With Tenofovir Monotherapy Followed by Concurrent Combination of Pegylated Interferon-Alpha-2b and Tenofovir or Tenofovir Monotherapy Followed by Sequential Therapy of Pegylated Interferon-Alpha-2b and Tenofovir in HBeAG-Positive Chronic Hepatitis B Patients With Raised ALT.", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants who responded to treatment", 
                "safety_issue": "No", 
                "time_frame": "Week 128"
            }, 
            {
                "measure": "Number of participants experiencing adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 128 weeks"
            }, 
            {
                "measure": "Number of participants discontinuing study therapy due to AEs", 
                "safety_issue": "No", 
                "time_frame": "Up to 104 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01727271"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}